What is Dragonor?
Dragonor (Dragonor) is an anti-epileptic drug, also called an anticonvulsant. Dragonor works by slowing down nerve impulses in the brain and affects chemicals that send pain signals across the nervous system.
Dragonor is a prescription medicine used to treat pain caused by damaged nerves in people with diabetes (diabetic neuropathy). Dragonor is also used to treat pain caused by damaged nerves (neuropathic pain) that follows healing of shingles (herpes zoster). This condition is called post-herpetic neuralgia.
.
It is not known if Dragonor is effective when used for the treatment of fibromyalgia, or when taken with other seizure medicines for adults with partial onset seizures.
Dragonor is supplied as extended-release tablets in the following strengths: 82.5 mg, 165 mg, and 330 mg.
Dragonor indications
Neuropathic Pain: Dragonor is indicated for the treatment of neuropathic pain in adults, including neuropathic pain associated with spinal cord injury.
Epilepsy: Dragonor is indicated as adjunctive therapy in adults with partial seizures, with or without secondary generalization.
Generalized Anxiety Disorder: Dragonor is indicated for the treatment of Generalized Anxiety Disorder (GAD) in adults.
Fibromyalgia: Dragonor is indicated for the management of fibromyalgia.
How should I use Dragonor?
Use Dragonor solution as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Dragonor solution comes with an extra patient information sheet called a Medication Guide. Read it carefully. Read it again each time you get Dragonor solution refilled.
- Take Dragonor solution by mouth with or without food.
- Use a measuring device marked for medicine dosing. Ask your pharmacist for help if you are unsure of how to measure your dose.
- Taking Dragonor solution at the same time each day will help you remember to take it.
- Take Dragonor solution on a regular schedule to get the most benefit from it.
- If you miss a dose of Dragonor solution, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Dragonor solution.
Uses of Dragonor in details
Use: Labeled Indications
Fibromyalgia (immediate release only): Management of fibromyalgia
Neuropathic pain associated with diabetic peripheral neuropathy (immediate release and extended release): Management of neuropathic pain associated with diabetic peripheral neuropathy
Neuropathic pain associated with spinal cord injury (immediate release only): Management of neuropathic pain associated with spinal cord injury
Postherpetic neuralgia (immediate release and extended release): Management of postherpetic neuralgia
Seizures, focal (partial) onset (immediate release only): Adjunctive therapy in patients ≥1 month of age with focal onset (partial-onset) seizures
Off Label Uses
Cough, chronic refractory
Data from a limited number of patients in a controlled trial suggest that Dragonor in combination with speech pathology therapy may be beneficial for the treatment of refractory chronic cough.
Based on the American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE) position statement on menopause, the Endocrine Society guideline on the treatment of symptoms of menopause, and the North American Menopause Society (NAMS) position statement on nonhormonal management of menopause-associated vasomotor symptoms, Dragonor is an effective and recommended alternative for the management of vasomotor symptoms associated with menopause in patients with contraindications to hormonal therapy or who prefer not to use hormonal therapy.
Dragonor description
Each capsule contains the following inactive ingredients: Mannitol, maize starch and talc.
Dragonor is described chemically as (S)-3-(aminomethyl)-5-methylhexanoic acid. The molecular formula is C8H17NO2 and the molecular weight is 159.23.
Dragonor is a white to off-white, crystalline solid with a pKa1 of 4.2 and a pKa2 of 10.6. It is freely soluble in water and both basic and acidic aqueous solutions. The log of the partition coefficient (n-octanol/0.05 M phosphate buffer) at pH 7.4 is -1.35.
Dragonor dosage
The dose range is 150 to 600 mg per day given in either two or three divided doses.
Epilepsy: Dragonor treatment can be started with a dose of 150 mg per day given as two or three divided doses. Based on individual patient response and tolerability, the dose may be increased to 300 mg per day after 1 week. The maximum dose of 600 mg per day may be achieved after an additional week.
Generalised Anxiety Disorder: The dose range is 150 to 600 mg per day given as two or three divided doses. The need for treatment should be reassessed regularly.
Dragonor treatment can be started with a dose of 150 mg per day. Based on individual patient response and tolerability, the dose may be increased to 300 mg per day after 1 week. Following an additional week, the dose may be increased to 450 mg per day. The maximum dose of 600 mg per day may be achieved after an additional week.
Discontinuation of Dragonor: In accordance with current clinical practice, if Dragonor has to be discontinued, it is recommended this should be done gradually over a minimum of 1 week independent of the indication.
Patients with Renal Impairment: Dragonor is eliminated from the systemic circulation primarily by renal excretion as unchanged drug. As Dragonor clearance is directly proportional to creatinine clearance, dose reduction in patients with compromised renal function must be individualised according to creatinine clearance (CrCl), as indicated in Table 1 determined using the following formula.
Dragonor is removed effectively from plasma by haemodialysis (50% of drug in 4 hours). For patients receiving haemodialysis, the Dragonor daily dose should be adjusted based on renal function. In addition to the daily dose, a supplementary dose should be given immediately following every 4-hour haemodialysis treatment.
Patients with Hepatic Impairment: No dose adjustment is required for patients with hepatic impairment.
Children: The safety and efficacy of Dragonor Sandoz in children below the age of 12 years and in adolescents (12-17 years of age) have not been established. No data are available.
Elderly (over 65 years of age): Elderly patients may require a dose reduction of Dragonor due to a decreased renal function.
Administration: Dragonor Sandoz may be taken with or without food.
Dragonor Sandoz is for oral use only.
Dragonor interactions
See also:
What other drugs will affect Dragonor?
Since Dragonor is predominantly excreted unchanged in the urine, undergoes negligible metabolism in humans (<2% of a dose recovered in urine as metabolites), does not inhibit drug metabolism in vitro and is not bound to plasma proteins, it is unlikely to produce or be subject to pharmacokinetic interactions.
Accordingly, in in vivo studies no clinically relevant pharmacokinetic interactions were observed between Dragonor and phenytoin, carbamazepine, valproic acid, lamotrigine, gabapentin, lorazepam, oxycodone or ethanol. Population pharmacokinetic analysis indicated that the oral antidiabetics, diuretics, insulin, phenobarbital, tiagabine and topiramate had no clinically significant effect on Dragonor clearance.
Co-administration of Dragonor with the oral contraceptives norethisterone and/or ethinyl oestradiol does not influence the steady-state pharmacokinetics of either substance. Dragonor may potentiate the effects of ethanol and lorazepam. In controlled clinical trials, multiple oral doses of Dragonor co-administered with oxycodone, lorazepam or ethanol did not result in clinically important effects on respiration. In the post-marketing experience, there are reports of respiratory failure and coma in patients taking Dragonor and other CNS depressant medications. Dragonor appears to be additive in the impairment of cognitive and gross motor function caused by oxycodone.
No specific pharmacodynamic interaction studies were conducted in elderly volunteers.
Dragonor side effects
See also:
What are the possible side effects of Dragonor?
The Dragonor clinical program involved over 8900 patients who were exposed to Dragonor, of whom over 5600 were in double-blind placebo-controlled trials. The most commonly reported adverse reactions were dizziness and somnolence. Adverse reactions were usually mild to moderate in intensity. In all controlled studies, the discontinuation rate due to adverse reactions was 12% for patients receiving Dragonor and 5% for patients receiving placebo. The most common adverse reactions resulting in discontinuation from Dragonor treatment groups were dizziness and somnolence.
In Table 2 all adverse reactions, which occurred at an incidence greater than placebo and in more than one patient, are listed by class and frequency (very common (≥1/10), common (≥1/100, <1/10), uncommon (≥1/1000, <1/100), rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
The adverse reactions listed may also be associated with the underlying disease and/or concomitant medicinal products.
In the treatment of central neuropathic pain due to spinal cord injury the incidence of adverse reactions in general, CNS adverse reactions and especially somnolence was increased.
Additional reactions reported from post-marketing experience are included in italics in Table 2.
After discontinuation of short-term and long-term treatment with Dragonor withdrawal symptoms have been observed in some patients. The following reactions have been mentioned: insomnia, headache, nausea, anxiety, diarrhoea, flu syndrome, convulsions, nervousness, depression, pain, hyperhidrosis and dizziness, suggestive of physical dependence. The patient should be informed about this at the start of the treatment.
Concerning discontinuation of long-term treatment of Dragonor, data suggest that the incidence and severity of withdrawal symptoms may be dose-related.
Dragonor contraindications
See also:
What is the most important information I should know about Dragonor?
You may have thoughts about suicide while taking this medication. Your doctor will need to check you at regular visits. Do not miss any scheduled appointments.
Call your doctor at once if you have any new or worsening symptoms such as: mood or behavior changes, depression, anxiety, insomnia, or if you feel agitated, hostile, restless, hyperactive (mentally or physically), or have thoughts about suicide or hurting yourself.
If you are taking Dragonor to prevent seizures, keep taking the medication even if you feel fine.
Do not stop using Dragonor without first talking to your doctor, even if you feel fine. You may have increased seizures or withdrawal symptoms such as headache, sleep problems, nausea, and diarrhea. Ask your doctor how to avoid withdrawal symptoms when you stop using Dragonor.
Do not change your dose of Dragonor without your doctor's advice. Tell your doctor if the medication does not seem to work as well in treating your condition.
Wear a medical alert tag or carry an ID card stating that you take Dragonor. Any medical care provider who treats you should know that you take seizure medication.
Active ingredient matches for Dragonor:
Pregabalin in Egypt.
List of Dragonor substitutes (brand and generic names) | Sort by popularity |
| Unit description / dosage (Manufacturer) | Price, USD |
| Dorene (Brazil) | |
| Dygab (Pakistan) | |
| ECOGAB (Pakistan) | |
| 100's (Forgo) | $ 12.65 |
| Ecogab Pregabalin 75 mg, mecobalamin750 mg. TAB / 100 (Forgo) | $ 12.65 |
| ECOGAB tab 10's (Forgo) | $ 1.27 |
| Ecogab Pregabalin 75 mg, mecobalamin750 mg. TAB / 100 (Forgo) | $ 12.65 |
| Ecubalin (Slovenia) | |
| Edgar (Tunisia) | |
| Egzysta (Croatia (Hrvatska), Greece, Slovakia) | |
| Elegya (Peru) | |
| Elumela (Bosnia & Herzegowina) | |
| Epiron (Bosnia & Herzegowina) | |
| ESVIGA (India) | |
| ESVIGA cap 75 mg x 10's (USV) | $ 0.99 |
| ESVIGA cap 150 mg x 10's (USV) | $ 1.75 |
| EZEGALIN | |
| EZEGALIN 75MG TABLET SR 1 strip / 10 tablet srs each (Eisai Pharmaceuticals India Pvt Ltd) | $ 1.16 |
| FIBAGIN (India) | |
| 75 mg x 100's (Sunrise) | $ 9.04 |
| 150 mg x 100's (Sunrise) | $ 16.27 |
| Fibagin 75mg TAB / 100 (Sunrise) | $ 9.04 |
| Fibagin 150mg TAB / 100 (Sunrise) | $ 16.27 |
| FIBAGIN tab 75 mg x 10's (Sunrise) | $ 0.90 |
| FIBAGIN tab 150 mg x 10's (Sunrise) | $ 1.63 |
| Fibagin 75mg TAB / 100 (Sunrise) | $ 9.04 |
| Fibagin 150mg TAB / 100 (Sunrise) | $ 16.27 |
| FRIDA (Spain) | |
| FRIDA tab 10's (Serum Institute) | $ 0.91 |
| Funxion (Philippines) | |
| Funxion cap 150 mg 30's (United Lab) | $ 36.32 |
| Funxion cap 50 mg 30's (United Lab) | $ 12.58 |
| Funxion cap 75 mg 30's (United Lab) | $ 23.11 |
| G Gab (Pakistan) | |
| Gaba- PM | |
| Gaba- PM Pregabalin 75mg, Mecobalamin500mcg CAP / 100 | $ 16.22 |
| Gaba-P (Bangladesh) | |
| GABA-PM (India) | |
| 100's (Hanburys) | $ 16.22 |
| Gaba-PM Pregabalin 75 mg, mecobalamin500 mcg. CAP / 100 (Hanburys) | $ 16.22 |
| GABA-PM cap 10's (Hanburys) | $ 1.62 |
| Gaba-PM Pregabalin 75 mg, mecobalamin500 mcg. CAP / 100 (Hanburys) | $ 16.22 |
| Gabaday SR (Turkey) | |
| Gabafit (India) | |
| Gabafit Capsule/ Tablet / 150mg / 10 units (Healtheon (Glenmark Pharmaceuticals Ltd.)) | $ 1.72 |
| Gabafit Capsule/ Tablet / 75mg / 10 units (Healtheon (Glenmark Pharmaceuticals Ltd.)) | $ 0.94 |
| Gabafit 75mg CAP / 10 (Healtheon (Glenmark Pharmaceuticals Ltd.)) | $ 0.84 |
| Gabafit 150mg CAP / 10 (Healtheon (Glenmark Pharmaceuticals Ltd.)) | $ 1.63 |
| 75 mg x 10's (Healtheon (Glenmark Pharmaceuticals Ltd.)) | $ 0.84 |
| 150 mg x 10's (Healtheon (Glenmark Pharmaceuticals Ltd.)) | $ 1.63 |
| Gabafit 150 mg Capsule (Healtheon (Glenmark Pharmaceuticals Ltd.)) | $ 0.17 |
See 1515 substitutes for Dragonor | |
References
- DailyMed. "PREGABALIN: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "Pregabalin". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "Pregabalin". http://www.drugbank.ca/drugs/DB00230 (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Dragonor are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Dragonor. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
